Paliperidone Teva (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidone Teva, is an atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is used to treat schizophrenia in adults and adolescents who require maintenance therapy. GNH USA supplies Paliperidone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone palmitate is an atypical antipsychotic indicated for the management of schizophrenia, acting on dopaminergic and serotonergic pathways to reduce psychotic symptoms. - Schizophrenia: Improves overall symptom control and reduces risk of relapse when administered as a monthly injection. - Schizoaffective disorder: Helps stabilize mood and psychotic symptoms as part of a comprehensive treatment plan. - Maintenance therapy for chronic psychotic disorders: Provides sustained drug exposure to support long‑term stability. - Adjunct to oral antipsychotics during transition: Allows gradual switch from oral to injectable formulation.

Paliperidone palmitate may cause a range of adverse reactions, from mild to serious. Monitoring and reporting are essential for patient safety.

Common Side Effects: - Injection site pain or erythema - Headache - Drowsiness or somnolence - Weight gain - Restlessness or akathisia - Nausea

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension - Elevated prolactin leading to galactorrhea - Seizures - Agranulocytosis

Before administering Paliperidone Teva, consider the following safety measures: - Assess  ". - Assess   d…  "  """"  " """  " "  ""  " "  … … … ...  "" "" "  ""  "" " … " \\  ". -  ". ",